ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran.
 PMID: 29026792       2017       Iranian journal of public health
Table: V179F


  Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
 PMID: 27231099       2016       Journal of the International AIDS Society
Table: V179F


  Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
 PMID: 27124362       2016       Journal of acquired immune deficiency syndromes (1999)
Introduction: However, in clinical trials individuals on an ETR containing regimen who experienced virological failure were infected with viruses that had a combination of RT mutations including V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S.


  Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
 PMID: 27120449       2016       PloS one
Discussion: Moreover, in combination with other mutations such as V90I, V106I, V179F, G190ASCVT and H221Y, it can synergistically exacerbate the resistance of ETR and RPV.


  Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.
 PMID: 26651266       2016       AIDS research and human retroviruses
Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing V90I, A98G, L100I/V, K101H/Q/T, K103R/S, V106A/I, V108I,
Result: Evidence of transmitted drug resistance was observed in 401 patients (8.7%), with RPV-RAMs Y181C, Y188L, K103S, V106A, V179F, and G190A/S detected as SDRMs.


  HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.
 PMID: 26414663       2016       AIDS research and human retroviruses
Abstract: Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M


  Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
 PMID: 26263403       2016       Antiviral therapy
Discussion: In the DUET studies, however, participants all had at least one baseline NNRTI mutation and treatment-emergent mutations at position E138 in the reverse transcriptase enzyme were also observed, in addition to the more frequent V179F/I and Y181C mutations.


  HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
 PMID: 26558396       2015       PloS one
Table: V179F


  Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naive and treated pediatric patients.
 PMID: 25674767       2015       Viruses
Table: V179F


  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
 PMID: 23934770       2014       The Journal of antimicrobial chemotherapy
Abstract: K101H, E138G, V179F and M230L mutations, associated with reduced susceptibility to etravirine and rilpivirine, were also associated with reduced susceptibility to nevirapine and/or efavirenz.



Browser Board

 Co-occurred Entities




   Filtrator